Cue Biopharma CFO resigns, elects Jill Broadfoot to board, increases authorized shares to 310M

Cue Biopharma, Inc.

CFO Kerri-Ann Millar resigns effective June 13, 2025; CEO Daniel Passeri will be interim principal financial and accounting officer.
Jill Broadfoot appointed to board and Audit Committee chair; granted option to purchase 48,800 shares.
Authorized shares of capital stock increased from 210M to 310M; common stock from 200M to 300M.
Stockholders approved 2025 Stock Incentive Plan (13.85M for, 2.01M against); also elected all director nominees.

item 5.02item 5.03item 5.07item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jill Broadfoot

Director

CUE · Cue Biopharma, Inc.

Effective: 2025-06-04
Filed: Jun 10, 2025 23:59 UTC

On June 4, 2025, Jill Broadfoot was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc. (the “Company”), the Audit Committee of the Board, and the Corporate Governance and Nominating Committee of the Board

Departed

Kerri-Ann Millar

Chief Financial Officer

CUE · Cue Biopharma, Inc.

Effective: 2025-06-13
Filed: Jun 10, 2025 23:59 UTC

On June 4, 2025, Kerri-Ann Millar notified the Company that she is resigning from her position as Chief Financial Officer, effective June 13, 2025.

Role change (interim)

Daniel R. Passeri

principal financial and accounting officer

CUE · Cue Biopharma, Inc.

Effective: 2025-06-13
Filed: Jun 10, 2025 23:59 UTC

Effective June 13, 2025, Daniel R. Passeri, the Company’s Chief Executive Officer, will serve as the Company’s principal financial and accounting officer on an interim basis until a new principal financial and accounting officer is designated.

Source: SEC EDGAR

accession 0000950170-25-084279

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.